Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Fig. 1

Study designs and flowcharts of (A) phase 1b, to determine the MTD and RP2D of binimetinib in combination with nivolumab (Arm 1A [Doublet]) and binimetinib in combination with nivolumab and ipilimumab (Arm 1B [Triplet]) and (B) phase 2 to determine the safety and clinical activity of the RP2D of binimetinib in combination with nivolumab (Arm 2A [Doublet]) and binimetinib in combination with nivolumab and ipilimumab (Arm 2B [Triplet]). BID, twice daily; DLT, dose-limiting toxicity; I-D, intermittent dosing; RP2D, recommended phase 2 dose; Q4W, every 4 weeks; Q8W, every 8 weeks

*Three weeks on, one week off

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us